Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled "The PEG Dilemma – A Solution," will take place on Tuesday, April 15, at 9:30 AM ET. The session will focus on addressing challenges related to anti-PEG antibodies in mRNA vaccines and therapeutics and introduces Serina's POZ-lipid technology as an immune-silent alternative to PEG-lipids.

Read more at globenewswire.com